Chengdu Kanghong Pharmaceuticals Group Co Ltd (002773) - Net Assets
Based on the latest financial reports, Chengdu Kanghong Pharmaceuticals Group Co Ltd (002773) has net assets worth CN¥9.58 Billion CNY (≈ $1.40 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥10.21 Billion ≈ $1.49 Billion USD) and total liabilities (CN¥631.40 Million ≈ $92.39 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 002773 intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥9.58 Billion |
| % of Total Assets | 93.82% |
| Annual Growth Rate | 19.45% |
| 5-Year Change | 51.92% |
| 10-Year Change | 219.28% |
| Growth Volatility | 13.6 |
Chengdu Kanghong Pharmaceuticals Group Co Ltd - Net Assets Trend (2009–2025)
This chart illustrates how Chengdu Kanghong Pharmaceuticals Group Co Ltd's net assets have evolved over time, based on quarterly financial data. See 002773 days of operational coverage to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Chengdu Kanghong Pharmaceuticals Group Co Ltd (2009–2025)
The table below shows the annual net assets of Chengdu Kanghong Pharmaceuticals Group Co Ltd from 2009 to 2025. For live valuation and market cap data, see Chengdu Kanghong Pharmaceuticals Group C market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥9.27 Billion ≈ $1.36 Billion |
+7.26% |
| 2024-12-31 | CN¥8.65 Billion ≈ $1.27 Billion |
+10.69% |
| 2023-12-31 | CN¥7.81 Billion ≈ $1.14 Billion |
+13.10% |
| 2022-12-31 | CN¥6.91 Billion ≈ $1.01 Billion |
+13.13% |
| 2021-12-31 | CN¥6.10 Billion ≈ $893.35 Million |
+6.07% |
| 2020-12-31 | CN¥5.76 Billion ≈ $842.26 Million |
+24.57% |
| 2019-12-31 | CN¥4.62 Billion ≈ $676.13 Million |
+13.14% |
| 2018-12-31 | CN¥4.08 Billion ≈ $597.61 Million |
+15.25% |
| 2017-12-31 | CN¥3.54 Billion ≈ $518.52 Million |
+21.98% |
| 2016-12-31 | CN¥2.90 Billion ≈ $425.08 Million |
+15.04% |
| 2015-12-31 | CN¥2.52 Billion ≈ $369.49 Million |
+56.66% |
| 2014-12-31 | CN¥1.61 Billion ≈ $235.85 Million |
+16.01% |
| 2013-12-31 | CN¥1.39 Billion ≈ $203.30 Million |
+25.60% |
| 2012-12-31 | CN¥1.11 Billion ≈ $161.87 Million |
+18.13% |
| 2011-12-31 | CN¥936.39 Million ≈ $137.02 Million |
+49.86% |
| 2010-12-31 | CN¥624.85 Million ≈ $91.44 Million |
+15.77% |
| 2009-12-31 | CN¥539.75 Million ≈ $78.98 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Chengdu Kanghong Pharmaceuticals Group Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2008.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥5.83 Billion | 62.73% |
| Other Components | CN¥3.47 Billion | 37.27% |
| Total Equity | CN¥9.30 Billion | 100.00% |
Chengdu Kanghong Pharmaceuticals Group Co Ltd Competitors by Market Cap
The table below lists competitors of Chengdu Kanghong Pharmaceuticals Group Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Data Patterns (India) Limited
NSE:DATAPATTNS
|
$2.71 Billion |
|
Servyou Software Group Co Ltd
SHG:603171
|
$2.71 Billion |
|
ATS Corporation
NYSE:ATS
|
$2.71 Billion |
|
Anhui Expressway Co Ltd
SHG:600012
|
$2.71 Billion |
|
California Water Service Group
NYSE:CWT
|
$2.71 Billion |
|
Bangkok Expressway and Metro Public Company Limited
BK:BEM
|
$2.71 Billion |
|
Bravida Holding AB
ST:BRAV
|
$2.71 Billion |
|
Olin Corporation
NYSE:OLN
|
$2.70 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Chengdu Kanghong Pharmaceuticals Group Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 8,653,202,130 to 9,298,916,486, a change of 645,714,356 (7.5%).
- Net income of 1,162,966,865 contributed positively to equity growth.
- Dividend payments of 552,673,862 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥1.16 Billion | +12.51% |
| Dividends Paid | CN¥552.67 Million | -5.94% |
| Other Changes | CN¥35.42 Million | +0.38% |
| Total Change | CN¥- | 7.46% |
Book Value vs Market Value Analysis
This analysis compares Chengdu Kanghong Pharmaceuticals Group Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.99x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 23.95x to 1.99x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | CN¥0.84 | CN¥20.10 | x |
| 2010-12-31 | CN¥0.96 | CN¥20.10 | x |
| 2011-12-31 | CN¥1.24 | CN¥20.10 | x |
| 2012-12-31 | CN¥1.40 | CN¥20.10 | x |
| 2013-12-31 | CN¥1.76 | CN¥20.10 | x |
| 2014-12-31 | CN¥2.04 | CN¥20.10 | x |
| 2015-12-31 | CN¥3.03 | CN¥20.10 | x |
| 2016-12-31 | CN¥3.33 | CN¥20.10 | x |
| 2017-12-31 | CN¥4.02 | CN¥20.10 | x |
| 2018-12-31 | CN¥4.70 | CN¥20.10 | x |
| 2019-12-31 | CN¥5.29 | CN¥20.10 | x |
| 2020-12-31 | CN¥6.26 | CN¥20.10 | x |
| 2021-12-31 | CN¥6.62 | CN¥20.10 | x |
| 2022-12-31 | CN¥7.51 | CN¥20.10 | x |
| 2023-12-31 | CN¥8.52 | CN¥20.10 | x |
| 2024-12-31 | CN¥9.44 | CN¥20.10 | x |
| 2025-12-31 | CN¥10.09 | CN¥20.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Chengdu Kanghong Pharmaceuticals Group Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 12.51%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 25.36%
- • Asset Turnover: 0.46x
- • Equity Multiplier: 1.07x
- Recent ROE (12.51%) is below the historical average (14.58%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | 15.27% | 12.92% | 0.78x | 1.53x | CN¥28.47 Million |
| 2010 | 17.59% | 13.63% | 0.80x | 1.61x | CN¥46.82 Million |
| 2011 | 17.83% | 16.23% | 0.78x | 1.40x | CN¥72.45 Million |
| 2012 | 18.56% | 15.23% | 0.90x | 1.36x | CN¥93.49 Million |
| 2013 | 23.01% | 21.38% | 0.87x | 1.24x | CN¥178.49 Million |
| 2014 | 17.18% | 16.33% | 0.86x | 1.22x | CN¥114.31 Million |
| 2015 | 15.74% | 18.98% | 0.72x | 1.16x | CN¥143.64 Million |
| 2016 | 17.10% | 19.56% | 0.68x | 1.29x | CN¥206.26 Million |
| 2017 | 18.18% | 23.12% | 0.61x | 1.29x | CN¥289.85 Million |
| 2018 | 17.02% | 23.82% | 0.56x | 1.27x | CN¥286.55 Million |
| 2019 | 15.54% | 22.05% | 0.56x | 1.26x | CN¥256.14 Million |
| 2020 | -4.69% | -8.19% | 0.47x | 1.22x | CN¥-845.43 Million |
| 2021 | 6.91% | 11.68% | 0.52x | 1.14x | CN¥-187.89 Million |
| 2022 | 12.99% | 26.46% | 0.44x | 1.12x | CN¥206.49 Million |
| 2023 | 13.39% | 26.40% | 0.46x | 1.09x | CN¥264.36 Million |
| 2024 | 13.77% | 26.75% | 0.48x | 1.08x | CN¥325.91 Million |
| 2025 | 12.51% | 25.36% | 0.46x | 1.07x | CN¥233.08 Million |
Industry Comparison
This section compares Chengdu Kanghong Pharmaceuticals Group Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $3,819,786,107
- Average return on equity (ROE) among peers: 5.04%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Chengdu Kanghong Pharmaceuticals Group Co Ltd (002773) | CN¥9.58 Billion | 15.27% | 0.07x | $2.71 Billion |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $5.88 Billion | 7.12% | 1.83x | $612.18 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $536.15 Million | 4.62% | 0.32x | $371.95 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $0.00 | 0.00% | 0.00x | $4.52 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $13.64 Billion | 12.57% | 0.51x | $2.56 Billion |
| Wedge Industrial Co Ltd (000534) | $549.14 Million | 1.31% | 0.01x | $2.22 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $893.64 Million | 25.78% | 0.79x | $12.90 Billion |
| Hainan Haiyao Co Ltd (000566) | $5.08 Billion | 1.71% | 1.08x | $734.70 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $271.26 Million | 1.07% | 1.01x | $324.84 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $1.60 Billion | -10.44% | 3.72x | $929.28 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $9.75 Billion | 6.63% | 0.12x | $3.13 Billion |
About Chengdu Kanghong Pharmaceuticals Group Co Ltd
Chengdu Kanghong Pharmaceutical Group Co., Ltd engages in the research, development, manufacture, and sale of pharmaceuticals and medical devices in China. It develops medicines for ophthalmic, neuropsychiatric, and others. The company was founded in 1996 and is headquartered in Chengdu, China.